F. J. Neumann, M. Sousa-uva, A. Ahlsson, F. Alfonso, A. P. Banning et al., ESC/EACTS Guidelines on myocardial revascularization, Eur Heart J, vol.40, pp.87-165, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02393795

L. Wallentin, R. C. Becker, A. Budaj, C. P. Cannon, H. Emanuelsson et al., Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes, N Engl J Med, vol.361, pp.1045-1057, 2009.

R. C. Becker, J. P. Bassand, A. Budaj, D. M. Wojdyla, S. K. James et al., Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial, Eur Heart J, vol.32, pp.2933-2944, 2011.

M. Valgimigli, H. Bueno, R. A. Byrne, J. P. Collet, F. Costa et al., ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS), Eur Heart J, vol.39, issue.3, pp.213-260, 2017.

A. El-menyar, M. Zubaid, W. Almahmeed, K. Sulaiman, A. Alnabti et al., Killip classification in patients with acute coronary syndrome: insight from a multicenter registry, Am J Emerg Med, vol.30, pp.97-103, 2012.

K. E. Szummer, S. D. Solomon, E. J. Velazquez, R. Kilaru, J. Mcmurray et al., Heart failure on admission and the risk of stroke following acute myocardial infarction: the VALIANT registry, Eur Heart J, vol.26, pp.2114-2119, 2005.

U. N. Khot, G. Jia, D. J. Moliterno, A. M. Lincoff, M. B. Khot et al., Prognostic Importance of Physical Examination for Heart Failure in Non-ST-Elevation Acute Coronary Syndromes, JAMA, vol.290, pp.2174-2181, 2003.

E. Von-elm, D. G. Altman, M. Egger, S. J. Pocock, P. C. Gøtzsche et al., The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies, PLoS Med, vol.4, issue.10, 2007.

, Observational Studies: Getting Clear about Transparency, The PLOS Medicine Editors, vol.11, issue.8, p.1001711, 2014.

. Authors/task-force, . Members, P. G. Steg, S. K. James, D. Atar et al., ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation, Eur Heart J, vol.33, pp.2569-2619, 2012.

S. D. Wiviott, E. Braunwald, C. H. Mccabe, G. Montalescot, W. Ruzyllo et al., Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes, N Engl J Med, vol.357, 2001.

K. Thygesen, J. S. Alpert, A. S. Jaffe, B. R. Chaitman, J. J. Bax et al., Fourth universal definition of myocardial infarction, Eur Heart J, vol.40, pp.237-269, 2018.

C. Vahdatpour, D. Collins, S. Goldberg, . Cardiogenic, and . Shock, J Am herat Assoc, vol.8, issue.8, p.11991, 2019.

J. H. Chesebro, G. Knatterud, R. Roberts, J. Borer, L. S. Cohen et al., Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge, Circulation, vol.76, pp.142-154, 1987.

T. Schuster, W. K. Lowe, and R. W. Platt, Propensity score model overfitting led to inflated variance of estimated odds ratios, J Clin Epidemiol, vol.80, pp.97-106, 2016.

M. A. Brookhart, S. Schneeweiss, K. J. Rothman, R. J. Glynn, J. Avorn et al., Variable selection for propensity score models, Am J Epidemiol, vol.163, pp.1149-1156, 2006.

B. Zhou, A. Latouche, V. Rocha, and J. Fine, Competing Risks Regression for Stratified Data, Biometrics, vol.67, issue.2, p.21155744, 2011.

B. Zhou, J. Fine, A. Latouche, and M. Labopin, Competing risks regression for clustered data, Biostatistics, vol.13, issue.3, pp.371-383, 2012.
URL : https://hal.archives-ouvertes.fr/hal-01125902

M. Orban, K. Mayer, T. Morath, I. Bernlochner, M. Hadamitzky et al., Prasugrel vs clopidogrel in cardiogenic shock patients undergoing primary PCI for acute myocardial infarction. Results of the ISAR-SHOCK registry, Thromb Haemost, vol.112, pp.1190-1197, 2014.

M. Orban, T. Limbourg, F. J. Neumann, M. Ferenc, H. G. Olbrich et al., ADP receptor antagonists in patients with acute myocardial infarction complicated by cardiogenic shock: a post hoc IABP-SHOCK II trial subgroup analysis, EuroIntervention, vol.10, issue.11, pp.1395-1403, 2016.

T. Killip and J. T. Kimball, Treatment of myocardial infarction in a coronary care unit, Am J Cardiol, vol.20, p.6059183, 1967.

A. Åkerblom, D. M. Wojdyla, L. Wallentin, S. K. James, F. De-souza-brito et al., Ticagrelor in patients with heart failure after acute coronary syndromes-Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial, Am Heart J, vol.213, pp.57-65, 2019.

H. Schotola, A. Brä-uer, K. Meyer, J. Hinz, F. A. Schö-ndube et al., Perioperative outcomes of cardiac surgery patients with ongoing ticagrelor therapy: boon and bane of a new drug, Eur J Cardiothorac Surg, vol.46, pp.198-205, 2014.

M. U. Zafar, D. A. Smith, U. Baber, S. Sartori, K. Chen et al., Impact of Timing on the Functional Recovery Achieved With Platelet Supplementation After Treatment With Ticagrelor, Circ Cardiovasc Interv, vol.10, issue.8, 2017.

R. Teng, G. F. Carlson, S. Nylander, and T. L. Andersson, Effects of autologous platelet transfusion on platelet inhibition in ticagrelor-treated and clopidogrel-treated subjects, J Thromb Haemost, vol.14, pp.2342-2352, 2016.

S. A. O'connor, J. Amour, A. Mercadier, R. Martin, M. Kerneis et al., Efficacy of Ex Vivo Autologous and In Vivo Platelet Transfusion in the Reversal of P2Y12 Inhibition by Clopidogrel, Prasugrel, and Ticagrelor: The APTITUDE Study, Circ Cardiovasc Interv, vol.8, issue.11, 2015.

R. F. Storey, D. J. Angiolillo, S. B. Patil, B. Desai, R. Ecob et al., Inhibitory Effects of Ticagrelor Compared With Clopidogrel on Platelet Function in Patients With Acute Coronary Syndromes, J Am Coll Cardiol, vol.56, pp.1456-1462, 2010.

S. Pehrsson, K. J. Johansson, A. Janefeldt, A. S. Sandinge, S. Maqbool et al., Hemostatic effects of the ticagrelor antidote MEDI2452 in pigs treated with ticagrelor on a background of aspirin, J Thromb Haemost, vol.15, pp.1213-1222, 2017.

E. Cerrato, M. Bianco, A. Bagai, L. De-luca, S. Biscaglia et al., Short term outcome following acute phase switch among P2Y12 inhibitors in patients presenting with acute coronary syndrome treated with PCI: A systematic review and meta-analysis including 22,500 patients from 14 studies, Int J Cardiol Heart Vasc, vol.22, pp.39-45, 2018.

J. Hong, R. D. Turgeon, and G. J. Pearson, Switching to Clopidogrel in Patients With Acute Coronary Syndrome Managed With Percutaneous Coronary Intervention Initially Treated With Prasugrel or Ticagrelor: Systematic Review and Meta-analysis, Ann Pharmacother, vol.53, pp.997-1004, 2019.

D. Gajanana, W. S. Weintraub, P. Kolm, T. Rogers, M. Iantorno et al., The impact of in-hospital P2Y12 inhibitor switch in patients with acute coronary syndrome, Cardiovasc Revasc Med, vol.19, pp.912-916, 2018.

P. A. Gurbel, K. P. Bliden, B. L. Hiatt, O. Connor, and C. M. , Clopidogrel for Coronary Stenting: Response Variability, Drug Resistance, and the Effect of Pretreatment Platelet Reactivity, Circulation, vol.107, pp.2908-2913, 2003.

D. J. Angiolillo, A. Ferná-ndez-ortiz, E. Bernardo, C. Ramírez, M. Sabaté et al., High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability, European Heart Journal, vol.25, pp.1903-1910, 2004.